Compare Quanta Services Inc (PWR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Repligen Corporation Common Stock — how do they compare? Quanta Services Inc trades at $647.65 (market cap $103.57B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Quanta Services Inc is far larger — about 9.3× Repligen Corporation Common Stock's market cap, and Quanta Services Inc pays a 0.06% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Repligen Corporation Common Stock for 0 Days on average.
| PWR | RGEN | |
|---|---|---|
Market Cap | $103.57B | $11.14B |
Volume | 1,036,513 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $785.24 | $194.57 |
52-Week Low | $412.21 | $102.87 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $109.67B | $11.02B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $660.53, down 4.93% for the day, but maintains strong analyst support with 27 buy ratings and a $802.08 consensus price target. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.24 surpassing expectations by 28%. Technical indicators show a bullish trend with support at $682 and resistance at $706. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025.
PWR presents a compelling growth story with strong earnings momentum and a record $53B backlog supporting future revenue. However, elevated valuation ratios (P/E 78.82, EV/EBITDA 35.6) and negative cash flow trends pose risks. The stock offers 21% upside to consensus targets, but investors should weigh premium valuation against execution risks in large infrastructure projects.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
